Quiver Bioscience platform is operational and ready for scale. Best #team , Amazing #science, Fastest CNS #drugdiscovery
Quiver Bioscience
生物技术研究
Cambridge，MA 4,167 位关注者
Decoding Brain Disease to Reimagine Drug Development
关于我们
Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through state-of-the-art proprietary engineering and AI/ML approaches.
- 网站
-
https://www.quiverbioscience.com
Quiver Bioscience的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，MA
- 类型
- 私人持股
- 创立
- 2013
- 领域
- Precision Medicine、Machine Learning、Genomics、Neurology、Drug Discovery、Personalized Medicine、Genetic Therapies、Optical Electrophysiology、Gene Editing、Stem Cells、Optogenetics、Transcriptomics、Human Models、Therapeutic Design & Screening、Cardiology、Rare Disease、Neurodegenerative、Disrupting Medicine和Functional Genomics
地点
-
主要
获取路线
179 Sidney Street
US，MA，Cambridge，02139
Quiver Bioscience员工
动态
-
The recently announced 2024 Nobel Prizes for Medicine, Physics, and Chemistry were all awarded for discoveries that are fundamental to Quiver's platform technology. We leverage these incredible technologies to accelerate CNS drug development and celebrate the new Nobel Laureates for their contributions! ?? Medicine - Victor Ambros and Gary Ruvkun for their discovery of microRNAs and their role in gene regulation (https://lnkd.in/dh7N-6zj) ?? Chemistry - David Baker, Demis Hassabis, and John Jumper for their development of approaches to design novel proteins and predict protein structures (the AI method, AlphaFold) (https://lnkd.in/eknNuN4C) ?? Physics - John Hopfield and Geoffrey Hinton for their groundbreaking work with artificial neural networks that has enabled current applications of machine learning (https://lnkd.in/dyUfXAtg) #NobelPrize The Nobel Prize #AI #ML #RNA #drugdiscovery https://lnkd.in/devWE52x
All Nobel Prizes 2024
nobelprize.org
-
Are you attending the Society for Neuroscience #SfN24 meeting? Stop by and chat with James Fink at his poster tomorrow and learn more about our Genomic Positioning System (GPS) technology! #neuroscience #drugdiscovery #CNS #AI #ML
-
-
Members of our team spent a beautiful morning participating in the first ever Boston Dup15q Alliance Believe Walk this past Saturday. It was a wonderful opportunity to connect with the local #Dup15q families and raise funds and awareness for chromosome 15q duplication syndrome (Dup15q).
-
-
As we approach the end of #PainAwarenessMonth here is another look at Quiver's commitment to discovering transformative, non-opioid pain therapeutics. #pain #neuroscience #drugdiscovery #AI
We recently published an innovative in vitro system for modeling chronic pain associated with osteoarthritis (OA), a condition that affects over 30 million patients in the US. Our Pain Therapeutics team, led by Hongkang Zhang and Owen McManus are leveraging the power of this model, which uses Quiver’s proprietary high-throughput all-optical electrophysiology platform, to develop novel non-opioid therapeutics for the treatment of pain disorders. The work, published in Pain – The Journal of the International Association for the Study of Pain, defines a “pain-in-a-dish” model that more accurately represents the relevant physiological environment for evaluating aspects of sensory neuron function associated with OA chronic pain in a scalable format needed to support therapeutic discovery. Furthermore, the data presented here supports the use of this model for effective phenotypic screening for novel pain therapeutics discovery and as a means to directly evaluate pharmacological effects of candidate molecules in a key tissue for pain signaling. “Our platform enables recordings from approximately 20,000 sensory neurons per multi-well plate with single-cell and single-action-potential resolution and it provides rich information content that is used to define OA pain phenotypes and mechanisms as well as characterize candidate therapeutic compounds” states Hongkang Zhang, a lead author on the manuscript. ? ?? | Read the full manuscript here: https://lnkd.in/dqK_BgC8 ? Summary: To establish the “pain-in-a-dish” model, the team first defined OA-SPARC (OA-derived Sensitizing Pain Reagent Composition), a mixture of inflammatory compounds known to be elevated in the joints of OA patients and demonstrated to elicit a pain response following injection into rat hind paw. OA-SPARC was applied to cultured rat dorsal root ganglion neurons and optogenetic recordings were obtained from individual neurons to interrogate a battery of electrophysiological features at high-throughput scale. Multidimensional analysis revealed a unique OA-SPARC-induced neuronal phenotype, characterized by increased excitability, which could be rescued by treatment with known analgesics. Finally, the curated OA-SPARC phenotype was used in a phenotypic screen of a library of roughly 3,000 small molecules including approved drugs and compounds targeting known neuronal signaling pathways. Confirmed hits shown to specifically reverse the OA-SPARC phenotype implicated select cell signaling pathways and molecular targets, including the MAPK pathway component MEK, in OA pain pathophysiology and suggest potential targets for therapeutic intervention. Quiver is continuing to develop and apply the OA-SPARC assay to evaluate pain phenotypes using human induced pluripotent stem cell-derived sensory neurons and enable discovery of improved pain therapeutics. #pain #neuroscience #drugdiscovery
-
-
Two members of our talented Data Science team, Dr. Steve Ryan and Dr. Caitlin Lewarch, will be presenting posters at the upcoming Society of Biomolecular Imaging and Informatics annual meeting this Thursday and Friday. We encourage you to stop by and hear from them about our unique drug discovery platform! #drugdiscovery #datascience #AI #neuroscience #SBI22024
-
-
We are thrilled to be participating in the #GenAI4Pharma NYC event tomorrow evening! Graham T. Dempsey, our founder and CSO, will be on site to present how Quiver leverages AI as a key component of our unique drug discovery platform. We are excited to be part of an incredible line-up of speakers from across biopharma. Amazon Web Services (AWS) Angelini Ventures Insilico Medicine RA Capital Management PTP
-
-
September is Pain Awareness Month and a time to recognize the millions of individuals worldwide who experience chronic pain. At Quiver Bioscience, we have developed a powerful drug discovery platform and robust in vitro pain models to enable discovery of novel pain therapeutics. Check out our recent poster (presented by Dr. Hongkang Zhang at this summer's International Association for the Study of Pain World Congress) which highlights some of our platform capabilities and efforts in pain therapeutics discovery! #drugdiscovery #neuroscience #pain #PainAwarenessMonth
-
Pain Therapeutic Lead Dr. Hongkang Zhang will be presenting tomorrow at the IASP (International Association for the Study of Pain) 2024 World Congress on Pain in Amsterdam. Be sure to connect with Hongkang if you are also attending to learn more about Quiver's powerful platform technology and how we use it to develop novel pain therapeutics! #drugdiscovery #chronicpain #WC2024 #IASP #pain #neuroscience
-
-
We are excited to participate in the 2024 ASF and Dup15q Alliance Research Symposium next week! James Fink will be speaking with updates on our Dup15q therapeutic program. Be sure to connect with us if you will also be attending! Dup15q Alliance #drugdiscovery #neuroscience #ASO #epilepsy #Dup15q
-